Detection of Resectable Recurrences in Colorectal Cancer Patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron Emission Tomography/computed Tomography

Overview

Journal Cancer Biother Radiopharm

Specialties Oncology
Pharmacology
Radiology

Date 2013 May 30

PMID 23713869

Citations 4

Authors

Nan-Jing Peng

Chin Hu

Tai-Ming King

Yu-Li Chiu

Jui-Ho Wang

Ren-Shyan Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: To evaluate the usefulness of 2-[(18)F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of resectable recurrences of colorectal cancer (CRC) and the impacts on the clinical disease management.

Methods: FDG-PET/CT was performed on patients with elevated serum carcinoembryonic antigen (CEA) levels >5 ng/mL (Group 1) or suspicious recurrences without rise in serum CEA levels (Group 2). The results were analyzed on the basis of histological data, disease progression, and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 6 months of the FDG-PET/CT scan. Resectable recurrences and changes in management were calculated based on medical records.

Results: In our study, 128 consecutive FDG-PET/CT analyses (n=49 in Group 1 and n=79 in Group 2) were performed on 96 recruited patients. Recurrences were proven in 63. The overall sensitivity, specificity, and accuracy of FDG-PET/CT were 98.4%, 89.2%, and 93.8%, respectively, and were 100%, 88.9%, and 95.9% in Group 1 and 96.9% and 89.4% and 92.4% in Group 2, respectively. Surgical resections were performed in 38.7% (12/31) of Group 1 patients and 53.1% (17/32) of Group 2 patients. FDG-PET/CT induced changes in planned management in 48.4% (62/128) of all patients, which included 63.3% (31/49) of Group 1 patients and 39.2% (31/79) of Group 2 patients (p=0.008). After a follow-up, 3.4% (1/29) of patients who underwent surgical resection of recurrent lesions and 34.3% (11/34) patients who did not undergo resection died at the end of study (p=0.004).

Conclusions: The surgical resection of limited recurrent disease, as determined by FDG-PET/CT, improves the survival of CRC patients. FDG-PET/CT should be performed not only in patients with elevated serum CEA levels, but also in those in whom recurrences are suspected to improve the early detection of resectable disease.

Citing Articles

Colorectal peritoneal metastases: Optimal management review.

Sanchez-Hidalgo J, Rodriguez-Ortiz L, Arjona-Sanchez A, Rufian-Pena S, Casado-Adam A, Cosano-Alvarez A World J Gastroenterol. 2019; 25(27):3484-3502.

PMID: 31367152 PMC: 6658395. DOI: 10.3748/wjg.v25.i27.3484.

Blood CEA levels for detecting recurrent colorectal cancer.

Nicholson B, Shinkins B, Pathiraja I, Roberts N, James T, Mallett S Cochrane Database Syst Rev. 2015; (12):CD011134.

PMID: 26661580 PMC: 7092609. DOI: 10.1002/14651858.CD011134.pub2.

Association between carcinoembryonic antigen levels and the applied value of F-fluorodeoxyglucose positron emission tomography/computed tomography in post-operative recurrent and metastatic colorectal cancer.

Bu W, Wei R, Li J, Wang L, Shi C, Song J Oncol Lett. 2014; 8(6):2649-2653.

PMID: 25364443 PMC: 4214442. DOI: 10.3892/ol.2014.2523.

Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges.

Young P, Womeldorph C, Johnson E, Maykel J, Brucher B, Stojadinovic A J Cancer. 2014; 5(4):262-71.

PMID: 24790654 PMC: 3982039. DOI: 10.7150/jca.7988.

References

Soyka J, Veit-Haibach P, Strobel K, Breitenstein S, Tschopp A, Mende K . Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?. J Nucl Med. 2008; 49(3):354-61. DOI: 10.2967/jnumed.107.048249. View

Shamim S, Kumar R, Halanaik D, Shandal V, Reddy R, Bal C . Role of FDG-PET/CT in detection of recurrent disease in colorectal cancer. Nucl Med Commun. 2010; 31(6):590-6. DOI: 10.1097/MNM.0b013e328338a120. View

Fukunaga H, Sekimoto M, Ikeda M, Higuchi I, Yasui M, Seshimo I . Fusion image of positron emission tomography and computed tomography for the diagnosis of local recurrence of rectal cancer. Ann Surg Oncol. 2005; 12(7):561-9. DOI: 10.1245/ASO.2005.08.001. View

Kim J, Czernin J, Allen-Auerbach M, Halpern B, Fueger B, Hecht J . Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med. 2005; 46(4):587-95. View

Chau I, Allen M, Cunningham D, Norman A, Brown G, Ford H . The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol. 2004; 22(8):1420-9. DOI: 10.1200/JCO.2004.05.041. View

Hillner B, Siegel B, Liu D, Shields A, Gareen I, Hanna L . Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008; 26(13):2155-61. DOI: 10.1200/JCO.2007.14.5631. View

Kievit J . Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur J Cancer. 2002; 38(7):986-99. DOI: 10.1016/s0959-8049(02)00061-8. View

Zeng Z, Cohen A, Urmacher C . Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum. 1993; 36(11):1063-8. DOI: 10.1007/BF02047301. View

McAfee M, Allen M, Trastek V, Ilstrup D, Deschamps C, Pairolero P . Colorectal lung metastases: results of surgical excision. Ann Thorac Surg. 1992; 53(5):780-5; discussion 785-6. DOI: 10.1016/0003-4975(92)91435-c. View

10.

Park I, Choi G, Lim K, Kang B, Jun S . Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Ann Surg Oncol. 2009; 16(11):3087-93. DOI: 10.1245/s10434-009-0625-z. View

11.

Tutt A, Plunkett T, Barrington S, Leslie M . The role of positron emission tomography in the management of colorectal cancer. Colorectal Dis. 2003; 6(1):2-9. DOI: 10.1111/j.1463-1318.2004.00592.x. View

12.

Saito Y, Omiya H, Kohno K, Kobayashi T, Itoi K, Teramachi M . Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thorac Cardiovasc Surg. 2002; 124(5):1007-13. DOI: 10.1067/mtc.2002.125165. View

13.

Desch C, Benson 3rd A, Somerfield M, Flynn P, Krause C, Loprinzi C . Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005; 23(33):8512-9. DOI: 10.1200/JCO.2005.04.0063. View

14.

Peng N, Liou W, Liu R, Hu C, Tsay D, Liu C . Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. Cancer Biother Radiopharm. 2011; 26(2):175-81. DOI: 10.1089/cbr.2010.0872. View

15.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

16.

Chen L, Tong J, Song H, Zhu H, Wang Y . (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2007; 13(37):5025-9. PMC: 4434629. DOI: 10.3748/wjg.v13.i37.5025. View

17.

Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

18.

Ike H, Shimada H, Ohki S, Togo S, Yamaguchi S, Ichikawa Y . Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum. 2002; 45(4):468-73; discussion 473-5. DOI: 10.1007/s10350-004-6222-0. View

19.

Nakamoto Y, Sakamoto S, Okada T, Senda M, Higashi T, Saga T . Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer. AJR Am J Roentgenol. 2006; 188(1):257-67. DOI: 10.2214/AJR.05.0708. View

20.

Benson 3rd A, Desch C, Flynn P, Krause C, Loprinzi C, Minsky B . 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000; 18(20):3586-8. DOI: 10.1200/JCO.2000.18.20.3586. View